Use of serum free light chain testing in nephrology;Utilizzo della determinazione delle catene leggere libere nel siero in ambito nefrologico

Biochimica Clinica

Volumn 37, Issue 5, 2013, Pages 352-356

  Fabbrini, Paolo ^a   Sirtori, Sonia ^a   Stella, Andrea ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; LIGHT CHAIN; NEPHROLOGY; REVIEW; SERUM FREE LIGHT CHAIN;

EID: 84889245496     PISSN: 03930564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Leung N, Rajkumar SV. Renal manifestations of plasma cell disorders. Am J Kidney Dis 2007;50:155-65.
2. Paueksakon P, Revelo MP, Horn RG, et al. Monoclonal gammopathy. Significance and possible causality in renal disease. Am J Kidney Dis 2003;42:87-95.
3. Solomon A, Waldmann TA, Fahey JL, et al. Metabolism of Bence Jones proteins. J Clin Invest 1964;43:103-17.
4. Hutchison CA, Batuman V, Behrens J, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol 2011;8:43-51.
5. Ying WZ, Wang PX, Sanders PW. Pivotal role of apoptosis signal-regulating kinase 1 in monoclonal free light chain-mediated apoptosis. Am J Pathol 2012;180:41-7.
6. Pasquali S, Iannuzzella F, Somenzi D, et al. Il coinvolgimento renale nelle discrasie plasmacellulari. G Ital Nefrol 2012;29:58-69.
7. Miettinen TA, Kekki M. Effect of impaired hepatic and renal function on Bence Jones protein catabolism in human subjects. Clin Chim Acta 1967;18:395-407.
8. Wochner RD, Strober W, Waldmann TA. The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J Exp Med 1967;126:207-21.
9. Katzmann JA, Clark JR, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-44.
10. Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008;3:1684-90.
11. Hutchison CA, Plant T, Drayson M, et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol 2008;22:9-11.
12. Park JW, Kim YK, Bae EH, et al. Combined analysis using extended renal reference range of serum free light chain ratio and serum protein electrophoresis improves the diagnostic accuracy of multiple myeloma in renal insufficiency. Clin Biochem 2012;45:740-4.
13. Sirac C, Bridoux F, Carrion C, et al. Role of the monoclonal κ chain V domain and reversibility of renal damage in a transgenic model of acquired Fanconi syndrome. Blood 2006;108:536-43.
14. Comenzo RL, Zhang Y, Martinez C, et al. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig VL germ line gene use and clonal plasma cell burden. Blood 2001;98:714-20.
15. Denoroy L, Déret S, Aucouturier P. Overrepresentation of the V κ IV subgroup in light chain deposition disease. Immunol Lett 1994;42:63-6.
16. Leung N, Gertz M, Kyle RA, et al. Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. Clin J Am Soc Nephrol 2012;7:1964-8.
17. Ivanhy B. Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma. Arch Pathol Lab Med 1990;114:986-7.
18. Hutchison CA, Cockwell P, Reid S, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007;18:886-95.
19. Hutchison CA, Cockwell P, Stringer S, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Nephrol 2011;22:1129-36.
20. Hutchison CA, Cook M, Heyne N, et al. European trial of free light chian removal by extended haemodialysis in cast nephropathy (EuLITE): a randomized control trial. Trials 2008;9:55.
21. Kastritis E, Migkou M, Gavriatopoulou M, et al. Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica 2009;94:300-2.
22. Hassoun H, Flombaum C, D'Agati VD, et al. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplant 2008;42:405-12.
23. Merlini G, Palladini G. Le catene leggere libere circolanti nella gestione del paziente con amiloidosi AL. Biochim Clin 2013;37:347-51.
24. Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-43.
25. Cohen G, Haag-WeberM, Mai B, et al. Effect of immunoglobulin light chains from hemodialysis and continuous ambulatory peritoneal dialysis patients on polymorphonuclear leukocyte functions. J Am Soc Nephrol 1995;6:1592-9.
26. Haynes R, Hutchison CA, Emberson J, et al. Serum free light chains and the risk of ESRD and death in CKD. Clin J Am Soc Nephrol 2011;6:2829-37.
27. Thilo F, Caspari C, Scholze A, et al. Higher serum levels of free κ plus λ immunoglobulin light chains ameliorate survival of hemodialysis patients. Kidney Blood Press Res 2011;34:344-9.